NBTX — Nanobiotix S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1760854 ·
Last close
$27.45
Market Cap
$1.39B
52W High
$57.14
52W Low
$19.14
ADV30
143,108
Next earnings
2026-09-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 128,331,000 | 110,891,000 | 161,713,000 |
| Dec 2025 | — | — | — | — | 67,760,000 | 52,750,000 | 152,243,000 |
| Jun 2025 | — | — | — | — | 45,174,000 | 28,818,000 | 114,126,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-34,288,000
Inventory
—
Receivables
$9,369,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,593,000
EBITDA
$-10,489,000
Free Cash Flow
$-7,894,125
Enterprise Value
$1,833,406,976
Total Cash
$52,750,000
Total Debt
$95,319,000
Shares Out
50,811,344
Trailing EPS
$-0.58
Book Value
$-2.02
ROE
—
ROA
-10.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 29,643,000 | -10,818,000 | -23,961,000 | 67,760,000 | 152,243,000 | -84,483,000 | -33,422,000 |
| Dec 2024 | -11,610,000 | -68,392,000 | -68,132,000 | 67,418,000 | 133,121,000 | -65,703,000 | -19,551,000 |
| Dec 2023 | 30,058,000 | -26,778,000 | -39,700,000 | 93,897,000 | 95,741,000 | -1,844,000 | -12,476,000 |
| Dec 2022 | 0 | -46,703,000 | -57,041,000 | 59,769,000 | 86,814,000 | -27,045,000 | -37,103,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.34
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $26.90 · call volume: 1 · put volume: 100Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | $1.40B | $22.56 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.41B | $23.76 | — |
| NUVB | Nuvation Bio Inc. | $1.37B | $3.90 | — |
| ANAB | ANAPTYSBIO, INC | $1.36B | $45.61 | — |
| TYRA | Tyra Biosciences, Inc. | $1.35B | $19.57 | — |
News headlines (Yahoo Finance, 1h cache)
Voting Rights and Shares Capital of the Company
2026-11-12 21:15 · Yahoo
Nanobiotix to Participate in Investor Conferences in November
2026-11-09 21:15 · Yahoo
Nanobiotix (ENXTPA:NANO) Could Be 46% Undervalued As Melanoma Trial Results Land
2026-10-26 23:31 · Yahoo
Nanobiotix stock gains on positive melanoma trial data
2026-10-26 15:35 · Yahoo
Nanobiotix (ENXTPA:NANO) Could Be 59% Undervalued After Its CFO Change
2026-10-10 17:11 · Yahoo
Can J&J’s Partnership Drive More Upside for Nanobiotix?
2026-09-28 19:31 · Yahoo
Nanobiotix (NBTX): Can Lung Tumor Control Justify Repeat Radiation Risks?
2026-09-17 17:06 · Yahoo
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
2026-10-24 11:00 · Yahoo
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
2026-10-01 20:15 · Yahoo
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
2026-09-24 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.